ANTITOXIN

ANTITOXIN

Munich, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.2M

Overview

Antitoxin GmbH is a well-established, privately-held German IVD manufacturer with a 58-year history as a reliable supplier in the niche field of blood typing reagents. The company operates as an expert OEM and bulk producer for global IVD leaders and local distributors, leveraging deep experience in transfusion medicine to develop and supply a comprehensive range of antisera, enzymes, and enhancers. Its core business is complemented by proprietary R&D in erythrocyte stabilization (Imu Solutions) and a novel point-of-care test card designed to prevent transfusion errors. As a revenue-generating entity, Antitoxin occupies a specialized position in the diagnostics supply chain, serving a critical but stable market with high-quality, certified products.

Infectious Disease

Technology Platform

Expertise in formulation and validation of immunological IVD reagents, particularly blood typing antisera. Proprietary R&D in erythrocyte stabilization (Imu Solutions) and development of wet chemistry point-of-care test cards for bedside ABO verification.

Funding History

2
Total raised:$18.2M
Series A$15M
Seed$3.2M

Opportunities

Growth is driven by the mandatory adoption of bedside ABO verification tests in European countries, creating a new market for its POC card.
Further opportunity lies in expanding its OEM partnerships, particularly with IVD companies in emerging markets, and commercializing its proprietary erythrocyte stabilization technology (Imu Solutions) to a wider customer base.

Risk Factors

Key risks include dependence on a limited number of large OEM customers, vulnerability to supply chain issues for human-derived plasma and erythrocytes, and the significant regulatory burden and cost of compliance with evolving IVD regulations like the EU IVDR, which could disrupt operations.

Competitive Landscape

Antitoxin competes in a specialized niche against other reagent specialists and the in-house production capabilities of large, integrated IVD corporations like Ortho Clinical Diagnostics (now part of QuidelOrtho), Bio-Rad, and Grifols. Its competitive edge is its deep expertise, long-standing reputation, comprehensive rare sera portfolio, and flexible OEM manufacturing model, rather than scale or breadth of product line.